Recent content by djaconi

  1. D

    All 19 Subjects in RepliCel's Clinical Trial Complete 6mos

    treatment: http://www.equities.com/news/news-story?val=176378982 :punk:
  2. D

    RepliCel Life Sciences releases Clinical Trials update

    "New treatment with great potential" http://editorial.equities.com/spotlight ... -on-track/
  3. D

    Clinical trials update

    Cell based treatment company called Replicel announces 6month update to their first in-man clinical trials: http://www.equities.com/news/news-story?val=172617813
  4. D

    Replicel may have New Treatment Option for Women

    "exciting new treatment" by Replicel: http://editorial.equities.com/spotlight ... for-women/
  5. D

    New Replicel procedure for women could be option

    This could be an "exciting new treatment"... http://editorial.equities.com/spotli...ion-for-women/
  6. D

    Replicel in the news again

    In latest news on Replicel they seem to be structuring company to generate appeal for additional financing. Also mentions their success in clinical trials: http://editorial.equities.com/spotlight-companies/replicel-converts-class-c-shares-to-common-stock/
  7. D

    Interview with Dr. Rolf Hoffman, Chief Medical Officer...

    For over a decade, leading hair biology scientists. Dr. Rolf Hoffmann and Dr. Kevin McElwee, have been studying the potential of dermal sheath cup cells to spark hair regeneration and the rejuvenation of miniaturized hair follicles. Hoffmann, RepliCel’s Chief Medical Officer, discusses his...
  8. D

    New Alopecia solution to be released this March

    Replicel CEO and bio-scientist speaks with Baldtalktruth.com about progress of their cell-based treatment and solution to pattern baldness: http://www.equities.com/blog/repcf-ceo- ... lktruthcom
  9. D

    Canada comp. provides update on first in-man clinical trial

    I have enormous faith and hope in this company, Replicel, out of Vancouver Canada. The companies entire C-level team consist of scientists and hair follicle regeneration experts. Here is a great article on their solutions: http://editorial.equities.com/spotlight ... ir-growth/
Top